SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment #7
Under the Securities Exchange Act of 1934
ONCOGENE SCIENCE, INC.
----------------------------
(Name of Issuer)
Common Stock par value $.01 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
682305 10 7
-----------------
(CUSIP Number)
Rebecca R. Tilden, Esq.
Vice President and Secretary, Hoechst Marion Roussel, Inc.
Vice President and Assistant Secretary, HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
(816) 966-4000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
July 23, 1997
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the
following box. [ ]
Page 1 of 6
Exhibit Index is at Page 6
<PAGE> 2
CUSIP No. 682305 10 7
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds WC
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 1,590,909*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 1,590,909*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 1,590,909*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 7.5%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Includes up to 500,000 shares that may be purchased for $5.50 per share
upon the exercise of a Common Stock Purchase Warrant during the five-year
period beginning December 11, 1994, and ending December 10, 1999.
<PAGE> 3
CUSIP No. 682305 10 7
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not Applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 1,590,909*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 1,590,909*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 1,590,909*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 7.5%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Includes up to 500,000 shares that may be purchased for $5.50 per share
upon the exercise of a Common Stock Purchase Warrant during the five-year
period beginning December 11, 1994, and ending December 10, 1999.
<PAGE> 4
The filing of this Amendment to the Statement on Schedule 13D (the
"Schedule 13D") with respect to the Common Stock of Oncogene Science, Inc.
(the "Issuer"), of Hoechst Marion Roussel, Inc., a Delaware corporation
("HMRI"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), shall
not be construed as an admission that Pharma is, for the purposes of
Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner
of any securities covered by this Statement.
This Statement on Schedule 13D is hereby amended to indicate the
filing of the following exhibits by incorporation by reference:
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
- ------- ---------------------------------
99.F Amended and Restated Collaborative Research and License Agreement
effective as of April 1, 1997, by and among HMRI, Hoechst AG, and
the Issuer (incorporated by reference to Exhibit 10.1 of the
Quarterly Report on Form 10-Q of the Issuer for the quarter ended
June 30, 1997)
99.G EPO Collaborative Research and License Agreement effective as of
January 1, 1997, by and between HMRI and the Issuer (incorporated
by reference to Exhibit 10.1 of the Quarterly Report on Form 10-Q
of the Issuer for the quarter ended March 31, 1997)
<PAGE> 5
SIGNATURES
----------
After reasonable inquiry and to the best of their knowledge and
belief, the undersigned certify that the information set forth in this
statement is true, complete and correct.
HOECHST MARION ROUSSEL, INC.
Date: August 18, 1997 By: /s/ Rebecca R. Tilden
Rebecca R. Tilden
Vice President
and Secretary
HMR PHARMA, INC.
Date: August 18, 1997 By: /s/ Rebecca R. Tilden
Rebecca R. Tilden
Vice President and
Assistant Secretary
<PAGE> 6
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ------------ ---------
99.F Amended and Restated Collaborative Research
and License Agreement effective as of April
1, 1997, by and among HMRI, Hoechst AG, and
the Issuer (incorporated by reference to
Exhibit 10.1 of the Quarterly Report on Form
10-Q of the Issuer for the quarter ended
June 30, 1997)*
99.G EPO Collaborative Research and License
Agreement effective as of January 1, 1997,
by and between HMRI and the Issuer
(incorporated by reference to Exhibit 10.1
of the Quarterly Report on Form 10-Q of the
Issuer for the quarter ended March 31, 1997)*
* Portions of this exhibit have been redacted and are the
subject of a confidential treatment request filed with
the Secretary of the Securities and Exchange Commission
by the Issuer pursuant to Rule 24b-2 under the Securities
Exchange Act of 1934, as amended.
